J Appl Biomed 1:127-139, 2003 | DOI: 10.32725/jab.2003.027

Amiodarone - excellent antiarrhythmic drug? (Happy end after 40 years of problems)

Petr Petr1,3,*, Miroslav Verner2, Chris J. Van Wyk4, Hendrik A. Koeleman4, Pavel Svítil5, Hana Kalová1,3,6
1 Clinical Pharmacology Ward, Hospital České Budějovice, 370 87 České Budějovice, Czech Republic
2 Departement of Clinical Biochemistry, Hospital České Budějovice, 370 87 České Budějovice, Czech Republic
3 Faculty of Health and Social Studies, South Bohemia University, 370 01 České Budějovice, Czech Republic
4 School of Pharmacy, Faculty of Health Sciences, Potchefstroom University for CHE, Republic of South Africa
5 Department of Internal Medicine and Cardiology, Hospital of Jihlava, 586 01 Jihlava, Czech Republic
6 EMA - European Medical Agency, Foundation/Fund, 370 01 České Budějovice, Czech Republic

Amiodarone, discovered forty years ago and in general use as an anti-anginal drug, has become a wide-spectrum anti-arrhythmic, used as the drug of preference in cardiac failure and after myocardial infarction, where it is the only drug (besides some betablockers) which does not increase overall mortality. It is successfully used in therapy and prophylaxis for life threatening arrhythmias, even when electro physiological testing has failed to disclose the detailed mechanism of arrhythmia. In cases of myocardial infarction it should be regarded as the anti-arrhythmic drug of first choice. Amiodarone is a drug which is capable with high probability of anticipating arrhythmias, combining, in an exclusive exceptional entity, beneficial effects on cardiac electrophysiology, neurochemical parameters, coronary flow and haemodynamics with a unique local antithyroid effect. A detailed survey of the current experimental and clinical basis for practical use is given, based on 93 cited sources from the last 30 years.

Keywords: anti-arrhythmic drug; electrophysiology; indications; interactions; adverse effects

Received: April 15, 2003; Published: July 31, 2003  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Petr P, Verner M, Van Wyk CJ, Koeleman HA, Svítil P, Kalová H. Amiodarone - excellent antiarrhythmic drug? (Happy end after 40 years of problems). J Appl Biomed. 2003;1(3):127-139. doi: 10.32725/jab.2003.027.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bartalena L., F. Bogazzi, E. Martino: Amiodarone induced thyrotoxicosis: a difficult diagnostic and therapeutic challenge. Clin. Endocrinol. 56: 33-38, 2002. Go to original source... Go to PubMed...
    2. Biran I. and I. Steiner: Coital headaches induced by amiodarone. Neurology. 58: 501-502, 2002. Go to original source... Go to PubMed...
    3. Bogazzi F., L. Bartalena, M. Gasperi, L.E. Braverman, E. Martino: The various effects of amiodarone on thyroid function. Thyroid 1: 511-519, 2001. Go to original source... Go to PubMed...
    4. Brembilla-Perrot B., O. Claudon, P. Houriez, D. Beurrier, C. Suty-Selton: Absence of change of signal - averaged electrocardiogram identifies patients with ventricular arrhytmias who are non responders to amiodarone. Int. J. Cardiol. 83: 47-55, 2002. Go to original source... Go to PubMed...
    5. Brilakis E.S., P.A. Friedman, B.J. Gersh, W.K. Shen: Oral amiodarone and atrial fibrillation. Lancet. 358: 47-149, 2001. Go to original source... Go to PubMed...
    6. Bytešník J.: Indication for the Amiodaron medication considering new findings. (In Czech). VI. Congress of Internal Medicine for Doctors in Practice with an International Participation, Zlín 1999.
    7. Bytešník J.: Management of arrhythmias with amiodarone in the light of new knowledge (In Czech). 42:193-199, 2000.
    8. Carlson B.O., B.N. Singh, M. Temciuc, S. Nilsson, Li Yi-Lin, Ch. Wellin, J. Malm: Synthesis and preliminary characterisation of a novel anti-arrhythmic compound KB 13 00 15. J. Med. Chem. 45: 623-630, 2002. Go to original source...
    9. Caron M. F., J. Kluger, C.M. White: Amiodarone in the new AHA guidelines for ventricular tachyarrhythmias Ann. Pharmacother. 45: 1248-1254, 2001. Go to original source... Go to PubMed...
    10. Chopra I. J., K. Baber: Use of oral cholecystographic agents in the treatment of amiodarone induced hyperthyroidism. J. Clin. Endocrinol. Metabol. 86: 4707-4710, 2001. Go to original source... Go to PubMed...
    11. Chouri N., T. Langin, S. Lantuejoul, M. Coulomb, C. Brambilla: Pulmonary nodules with CT halo sign. Respiration 69:103-106, 2002. Go to original source... Go to PubMed...
    12. Chung W. H., B.M. Bennett, W.J. Racz, J.F. Brien, T.E. Massey: Induction of c-jun and TGF-beta 1 Fischer 344 rats during amiodarone-induced pulmonary fibrosis. Amer. J. Physiol. 28l: 110-118, 2001. Go to original source...
    13. David I.: Perioperative tachyarrhythmia (In Czech). Čas. Lék. Čes. 13: 403- 410, 2002.
    14. Dorian P., D. Cas, B. Schwartz, R. Cooper, R. Gelaznikas, A. Barr: Amiodarone as compared with lidocaine for shock resistant ventricular fibrillation. New Engl. J. Med. 346: 884-890, 2002. Go to original source... Go to PubMed...
    15. Dubin A.M., G.F. Van Hare, K.K. Collins, D. Bernstein, D.N. Rosenthal: Survey of current practices in use of amiodarone and implatable cardio verter Defibrillators in paediatrics patients with end-stage heart failure. American J. Cardiol. 88: 809-810, 2001. Go to original source... Go to PubMed...
    16. Eaton S.E.M., H.A. Euinton, C.M. Newman, A.P. Weetman, W. Bennet: Clinical experience of amiodarone-induced therotoxicosis over a 3-year period: role of colour-flow Doppler sonography. Clin. Endocrinol. 56: 33-38, 2002. Go to original source... Go to PubMed...
    17. Fejfar Z., J. Dvořák, V.Pidrmann: Workshop on Cardiology (In Czech). Session of Czech Medical Society of J.E. Purkyně, Zlín 1980.
    18. Galperin J., M.V. Elizari, P.A. Chiale, R.T. Molina, R. Ledesma, A.O. Scapin, M. Vazquez Blanco: Efficacy of amiodarone for the termination of chronic atrial fibrillation and maintenance of normal sinus rhythm: a prospective, multicenter, randomised, controlled, double blind trial. J. Cardiovasc. Pharmacol. Ther. 6: 341-350, 2001. Go to original source... Go to PubMed...
    19. Gough I.R., J. Gough: Surgical management of amiodarone-associated thyrotoxicosis. Med. J. Austral. 176: 128-129, 2002. Go to original source... Go to PubMed...
    20. Grupcheva C., C.N.J. McGhee: In vivo confocal microscopy of patients with amiodarone-induced keratopathy. Cornea. 21: 430-432, 2002. Go to original source... Go to PubMed...
    21. Ha H.R., P. Kozlik, B. Stieger, L. Bigler, F. Follath: Metabolism of amiodarone. High performance liquid chromatography assay for mono-N-desethylamiodarone hydroxylation in liver microsomes. J. Chromat. 757: 309 - 315, 2001. Go to original source...
    22. Haan C.K. and S.A. Geraci: Role of amiodarone in reducing atrial fibrillation after cardiac surgery inj adults. Ann. Thor. Surg. 73: 1665-1669, 2002. Go to original source... Go to PubMed...
    23. Herold M.: Sudden death and implantable cardioverters-defibrillators (In Czech). www.zdr.cz/ZN02924/, pp.16 -17.
    24. High W.A. and S.D. Weiss: Images in clinical medicine, Pigmentation related to amiodarone. New Engl. J. Med. 345: 1464, 2001. Go to original source... Go to PubMed...
    25. Hilleman D. E. and S.A. Spinler: Conversion of recent- onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trials. Pharmacotherapy. 22: 66 - 74, 2002. Go to original source... Go to PubMed...
    26. Ikaheimo K., R. Kettunen, M. Mantyjarvi: Visual functions and adverse ocular effects in patients with amiodarone medication. Acta Ophtalmol. Scand. 80: 59-63, 2002. Go to original source... Go to PubMed...
    27. James P.R. and G.C. Barrera: Intravenous amiodarone in intensive care: time for a reappraisal? Inten. Care Med. 8: 1433, 2001. Go to original source... Go to PubMed...
    28. Jirásková M.: Phototoxicity and photoallergy as side effects of drugs from a dermatologist's point of view (In Czech). Remedia 1: 271-276, 2001.
    29. Jun A.S. and D.R. Brocks: High-performance liquid chromatography assay of amiodarone in rat plasma. J. Pharm. Pharmaceut. Sci. 3: 263-368, 2001.
    30. Kaushik S., A. Hussain, P. Clarke, H.L. Lazar: Acute pulmonary toxicity after low-dose amiodarone therapy. Ann. Cardiothor. Surg. 72: 1760-1761, 2001. Go to original source... Go to PubMed...
    31. Kaye D.M., A.M. Dart, G.L. Jennings, M.D. Esler: Antiadrenergic effect of chronic amiodarone therapy in human heart failure. Journal of the Amer. Coll. Cardiol. 33: 1533-1539, 1999. Go to original source... Go to PubMed...
    32. Kharabseh S., C. Abendroth, M. Kozak: Fatal pulmonary toxicity occurring within two weeks of initiation of amiodarone. Amer. J. Cardiol. 89: 896-898, 2002. Go to original source... Go to PubMed...
    33. Kerin N.Z., K. Faitel, I.A. Kerin, L. Quinones, R.J. Stomel: Efficacy of low - dose amiodarone in the prevention of paroxysmal atrial fibrillation resistant to type I A anti-arrhythmic drugs. Amer. J. Ther. 7: 245-250, 2000. Go to original source... Go to PubMed...
    34. Kim M.H., W. Rachwal, C. McHale, D. Bruckman, B.F. Decena, P. Rusman, F. Morady, K.A. Eagle: Effect of amiodarone, diltiazem, beta-blocker on frequency of atrial fibrillation, length of hospitalisation and hospital costs after coronary artery bypass grafting. Amer. J. Cardiol. 89: 1126-1128, 2002. Go to original source... Go to PubMed...
    35. Kontoyannis D.A., M.I. Anastasiou, S.A. Kontoyannis, A.K. Zaga, J.N. Nanas: Intravenous amiodarone decreases the duration of atrial fibrillation associated with acute myocardial infarction. Cardiovasc. Drugs Ther. 15: 155- 60, 2001. Go to original source... Go to PubMed...
    36. Kovoor P., V. Eipper, K. Byth, M.J. Cooper, D.L. Ross: Comparison of sotalol with amiodarone for long- term treatment of spontaneous sustained ventricular tachyarrhythmia based on coronary artery disease. Eur. Heart J. 20: 364-374, 1999. Go to original source... Go to PubMed...
    37. Lau W., D. Newman, P. Dorian: Can anti-arrhythmic agents be selected based on mechanism of action? Drugs 60: 1315-1328, 2000. Go to original source... Go to PubMed...
    38. Leung P.M., N.D. Quinn, P.E. Belchetz: Amiodarone-induced thyrotoxicosis: not a benign condition. Int. J. Clin. Pract. 56: 4-6, 2002. Go to original source... Go to PubMed...
    39. Levy S.: Pharmacologic management of atrial fibrillation: current therapeutic strategies. Amer. Heart J. 141: 15-21, 2001. Go to original source... Go to PubMed...
    40. Levy S. and P. Ricard: Using the right drug: a treatment algorithm for regular supraventricular taxhycardia. European Heart Journal. 18: 27-32, 1997. Go to original source... Go to PubMed...
    41. Lüllmann H., K. Mohr, M. Wehling: Pharmacology and Toxikology (In Czech). Avicenum/Grada Publishing, Praha 2002, pp. 694.
    42. Macaluso D.C., W.T. Shults, F.T. Fraunfelder: Features of amiodarone-induced optic neuropathy. American Journal of Ophtalmology. 127: 610-612, 1999. Go to original source... Go to PubMed...
    43. Malik M., A.J. Camm, M.J. Janse, D.G. Julian, G.A. Frangin, P.J. Schwartz: Depressed Heart Rate Variability Identifies Post infarction Patients Who Might Benefit From prophylactic Treatment With Amiodarone. A sub study of EMIAT (The European Myocardial Infarction Amiodarone Trial) J. Amer. Coll. Cardiol. 35: 1263-1275, 2003. Go to original source...
    44. Manolis A. G., A.G. Katsivas, C. Vassilopoulos, C.G. Tsatiris: Electrical storms in an ICD-recipient with 429 delivered appropriate shocks: therapeutic management with anti-arrhythmic drug combination. J. Interven. Card. Electrophysiol. 6: 91-94, 2002. Go to original source... Go to PubMed...
    45. Marek J. (ed.): Pharmacotherapy of Internal Diseases (In Czech). Avicenum/Grada Publ., Praha 1998, pp. 743.
    46. Matsuyama T., K. Tanno, Y. Kobayashi, C. Obara, S. Ryu, T. Adachi, H. Ezumi, T. Asano, A. Miyata, S. Koba, T. Baba, T. Katagiri: T wave alternant for predicting adverse effects of amiodarone in a patient with dilated cardiomyopathy. J. Circ. J. 65: 468-470, 2001. Go to original source... Go to PubMed...
    47. Medicamenta Nova (In Czech), Symposium LS JEP, Praha 1983.
    48. Mendez M., V. Parera, R. Enriquez de Salamanca, A. Battle: Amiodarone is a pharmacologically safe drug for porphyries, Gen. Pharmacol.. 32: 259-263, 1999. Go to original source... Go to PubMed...
    49. Meng X., P. Mojaverian, M. Doedee, E. Lin, I. Weinryb, S.T. Chiang, P.R. Kowey: Bioavailability of amiodarone tablets administered with and without food in healthy subjects. Amer. J. Cardiol. 87: 432-435, 2001. Go to original source... Go to PubMed...
    50. Micuda S., M. Hodac, L. Sispera, P. Parizek, M. Pleskot, G. Zimova, J. German, J. Martinkova, V. Pidrman: Influence of amiodarone on urinary excretion of beta-hydrocortisol in humans. Physiol. Res. 50: 191-196, 2001.
    51. Moorthy R.S. and S. Valluri: Ocular toxicity associated with systemic drug therapy. Curr. Opin. Ophtalmol. 10: 438-446, 1999. Go to original source... Go to PubMed...
    52. Mutschler E.: Arzneimittel - Wirkungen, Pharmakology and Toxikology textbook Wisentschaftliche Verlaggesellschaft mbH. Stuttgart 1991, pp. 879.
    53. Nagele H., R. Schomburg, B. Petersen, W. Rodiger: Dual chamber pacing in patients with severe heart failure on beta blocker and amiodarone treatment: preliminary results of a randomised study. Heart 87: 566-567, 2002. Go to original source... Go to PubMed...
    54. Naganuma M., T. Shiga, K. Nishikata, T. Tsuchiya, H. Kasanuki, E. Fujii: Role of desethylamiodarone in the antikoagulant effect of concurrent amiodarone and warfarin therapy, J. Cardiovasc. Pharmacol. Ther. 6: 363 -367, 2001. Go to original source... Go to PubMed...
    55. Nakajima K., K. Yamazaki, E. Yamada, Y. Kanaji, S. Kosaka, K. Sato, K. Takano: Amiodarone stimulates interleukin-6 production in cultured human thyrocytes, exerting cytotoxic effects on thyroid follicles in suspension culture. Thyroid 11: 101-109, 2001. Go to original source... Go to PubMed...
    56. Neužil P., M. Táborský, L. Šedivá, P. Niederle: Radiofrequency ablation of auricular flutter in patients with long-term treatment of auricular fibrillation with amiodarone: application of hybrid therapy (In Czech), Prakt. lék. 81: 208-211, 2001.
    57. Noble S.L., W.H. Reploge, S.R. Dickey: Amiodarone for the treatment of persistent atrial fibrillation. J. Fam. Pract. 48: 34 - 335, 1999.
    58. Opincariu M., A. Varro, N. Iost, L. Virag, O. Hala, J. Szolnoki, J. Szecsi, G. Bogats, P. Szenohradszky, P. Matyus, J.G. Papp: The cellular electro physiologic effect of GYKI 16638, a new anti-arrhythmic compound, Curr. Med. Chem. 9: 41-46, 2002. Go to original source... Go to PubMed...
    59. Osman F., J.A. Franklyn, M.C. Sheppard, M.D. Gammage: Succesfull treatment of amiodarone-induced thyrotoxicosis. Circulation 105: 1275-1277, 2002. Go to original source...
    60. Petr P.: Final Report on Clinical Testing of Cordarone (amiodarone) Krka inj. in Patients ith AMI (In Czech), Clinical Research Report Series, Novo Město, Yugoslavia, 1986.
    61. Pitsiavas V., P. Smerdely, S.C. Boyages: Amiodarone compared with iodine exhibits a potent and persistent inhibitory effect on TSH-stimulated CAMP production in vitro: a possible mechanism to explain amiodarone-induced hypothyroidism. Eur. J. Endocrinol. 140: 241-249, 1999. Go to original source... Go to PubMed...
    62. Pleskot M.,Pařízek P., Hodač M., Haman L., Šťástek J., Červinka P., Tauchman M.: Ventricular fibrillation in chronic heart disease (In Czech). Vn. Lék. 46: 80-86. 2000.
    63. Pleskot M., P. Pařízek, M. Hodač, L. Haman, J. Šťástek, P. Červinka, M. Tauchman: Revascularisation of the myocardium and electrical instability of the ventricles (In Czech). Vn. lék. 45: 75-80.
    64. Polak B.C., N.P.A. Tutein, E. Rietveld: Visual impairment due to optic neuropathy in 2 patients on amiodarone or ethambutol and isoniazide therapy. Nederland tiejdschrift voor geneeskunde (In Dutch). 145: 922-926, 2001.
    65. Poll L.W., P. May, J.A. Koch, G. Hetzel, P. Heering, U. Modder: HRCT findings of amiodarone pulmonary toxicity: clinical and radiology regression, J. Cardiovasc. Pharmacol. Ther. 6: 307-311, 2001. Go to original source... Go to PubMed...
    66. Reddy Prahashni, B. Dunn Alisha, C.M. White, J.P. Tsikouris, G. Satyendra, J. Kluger: An economic analysis of amiodarone versus placebo for the prevention of atrial fibrillation after open heart surgery. Pharmacotherapy 22: 75-80, 2002. Go to original source... Go to PubMed...
    67. Reithmann C., U. Dorwarth, A. Gerth, T. Remp, G. Steinbeck, E. Hoffmann: Early reinitiation of atrial fibrillation following an external electrical cardioversion in amiodarone- treated patients. J. Intervent. Card. Electrophysiol. 5: 285-292, 2001. Go to original source... Go to PubMed...
    68. Routitie F., J.P. Boissel, S.J. Conolly, A.J. Camm, J.A. Cairns, D.G. Julian, M. Gent, M.J. Janse M.J., P. Dorian, G. Frangin: Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarction Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Amiodarone Trial) database, The EMIAT and CAMIAT Investigators, Circulation 99: 2268 - 2275, 1999. Go to original source... Go to PubMed...
    69. Sangha S., P. Uber, M. Mehra: Difficult cases in heart failure: amiodarone lung injury: another heart failure mimic? Congest Heart Fail. 8: 93-96, 2002. Go to original source... Go to PubMed...
    70. Sanoski C.A., J.L. Bauman: Clinical observations with the amiodarone/warfarin interaction: dosing relationship with long-term therapy. Chest. 121: 19-23, 2002. Go to original source... Go to PubMed...
    71. Sheikzadeh A., U. Schafer, A. Schnabel: Drug-induced lupus erythematosus by amiodarone, Arch. Intern. Med. 162: 834-836, 2002. Go to original source... Go to PubMed...
    72. Scharf C., E.N. Oechslin, F. Salomon, W. Kiowski: Clinical picture: Amiodarone-induced pulmonary mass and cutaneous vasculitis. Lancet 358: 2045, 2001. Go to original source... Go to PubMed...
    73. Schlant R. C., J.J. Collins jr., M.A. Engle, R.L. Frye, N.M. Kaplan, R.A. O ŕourke: Yearbook of Cardiology, Mosby-Year Book Inc., 1992, pp. 441.
    74. Schlapfer J., F. Rapp, L. Kappenberger, M. Fromer: Electro physiologically guided amiodarone therapy versus the implantable cardioverter-defibrillator for sustained ventricular tachyarrhythmias after myocardial infarction: results of long-term follow-up. J. Amer. Coll. Cardiol. 39: 1813-1819, 2002. Go to original source...
    75. Starmer C. F.: The cardiac vulnerable period and re-entrant arrhythmias: targets of anti- and pro-arrhythmic processes. Pac. Clin. Electrophysiol. 20: 4456-4454, 1997. Go to original source... Go to PubMed...
    76. Stewart C.E.: Amiodarone for ACLS: a critical evaluation. Emerg. Med. Serv. 30: 61-67, 2001.
    77. Suchopár J., ed. Remedia: Compendium Panax Publ. (In Czech). Prague 1997.
    78. Škop B. (ed.): AISLP, Automated Information System of Medical Preparations (In Czech). Computer Programme, Praha 2003.
    79. Špinar J., J. Vítovec, L. Kubecová, J. Pa řenica: Clinical Trials in Cardiology (In Czech). Avicenum/Grada Publ., Praha 2001, pp. 487.
    80. Tardos L., L. Szekeres, J.G. Papp: Pharmacological Control of Heart and Circulation Ed., Advances in Pharmacological Research and Practice, Gen. Ed. J. Knoll Pergamon Press, Budapest 1979, pp. 439.
    81. Tokmakoglu H., O. Kandemir, S. Gunyadin, Z. Catav, C. Yorgancioglu, Y. Zorlutuna: Amiodarone versus digoxin and metoprolol combination for the prevention of postcoronary Bypass atrial fibrillation, Eur. J. Thor. Cardiovasc. Surg. 21: 401-405, 2002. Go to original source...
    82. Tsikouris J. P. and C.D. Cox: A review of class III anti-arrhythmic agents for atrial fibrillation: maintenance of normal sinus rhythm. Pharmacotherapy 12: 1514-1529, 2001. Go to original source... Go to PubMed...
    83. Vanbesien J., A. Casteels, A. Bougatef, L. De Catte, W. Foulon, S. De Bock, J. Smitz, J. De Schepper: Transient fetal hypothyreoidism due to direct fetal administration of amiodarone for drug resistant fetal tachycardia, Amer. J. Perinat. 18: 113-116, 2001. Go to original source... Go to PubMed...
    84. Veloso H.H.: Is amiodarone the first or the last choice for the maintenance of sinus rhythm after successful conversion of atrial fibrillation? Medical science monitor: international medical J. Exp. Clin. Res. 7: 526-530, 2001.
    85. Weirich J., W. Wenzel: Aktuelle Einteilung antiarrhytmisch wirksamer Substanzen. Freiburg Z. Kardiol. 89: 62-67, 2000. Go to original source...
    86. What is What 1997: a guide to acronyms for cardiovascular trials. 4th edition, Astra-Hässle, Mölndal 1997.
    87. Wichterle D.: The rationale for amiodarone treatment after acute myocardial infarction- will we be given a unequivocal definition of target patients' population? (In Czech) JACC-CZ 2: 321-322, 2000.
    88. Widimský J.: Amiodarone treatment safety. VI. Congress of Internal Medicine with an International Participation for Doctors in Practice (In Czech), Symposium fy Sanofi-Synthélabo, Zlín 1999.
    89. Widimsky J.: The side effects of amiodarone (In Czech). Cor Vasa 2000: pp. 235-242.
    90. Wurderman R.L., Moos A.N., Mohiuddin Seyed M., Lenz T.L.: Amiodarone vs. Sotalol as prophylaxis against atrial fibrillation/flutter after heart surgery: a meta-analysis. Chest 121: 1203-1210, 2002. Go to original source... Go to PubMed...
    91. Ybarra J., D. Fuster, F. Martin, F. Lomena, J.V. Torregrossa: Clinical picture: amiodarone-induced thyreoiditis. Lancet. 359: 69, 2002. Go to original source... Go to PubMed...
    92. Yung A., K. Agnew, J. Snow, F. Oliver: Two unusual cases of toxic epidermal necrolysis. Austr. J. Dermatol. 43: 35-38, 2002. Go to original source...
    93. The search for novel anti-arrhythmic strategies. Sicilian Gambit. Jap. Circ. J. 62: 633-648, 1998.

    Return to the content